Trial
NCT04788043
Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Ranjana Advani
Collaborators
Merck Sharp & Dohme LLC
Condition
Hodgkin Lymphoma
Intervention
Magrolimab
Why stopped
Discontinuation of magrolimab development
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-06-30